Search Results
Found 2 results
510(k) Data Aggregation
K Number
K241313Device Name
OHC COVID-19 Antigen Self Test
Manufacturer
Osang LLC
Date Cleared
2025-05-30
(386 days)
Product Code
QYT
Regulation Number
866.3984Why did this record match?
Applicant Name (Manufacturer) :
Osang LLC
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
Output the intended / indications for use exactly as it appears in the overview without any additional commentary or backticks:
The OHC COVID-19 Antigen Self Test is a visually read lateral flow immunoassay device intended for the rapid, qualitative detection of SARS-CoV-2 nucleocapsid protein antigens directly in anterior nasal swab specimens from individuals with signs and symptoms of COVID-19.
This test is for non-prescription home use by individuals aged 14 years and older testing themselves, or adults testing individuals aged 2 years or older.
All negative results are presumptive. Symptomatic individuals with an initial negative test result must be re-tested once between 48 and 72 hours after the first test using either an antigen test or a molecular test for SARS-CoV-2. Negative results do not rule out infection with SARS-CoV-2 or other pathogens and should not be used as the sole basis for treatment.
Positive results do not rule out co-infection with other respiratory pathogens.
This test is not a substitute for visits to a healthcare provider or appropriate follow-up and should not be used to determine any treatments without provider supervision. Individuals who test negative and experience continued or worsening COVID-19 like symptoms, such as fever, cough and/or shortness of breath, should seek follow up care from their healthcare provider.
The performance characteristics for SARS-CoV-2 were established from June 2023 to July 2023 when SARS-CoV-2 Omicron was dominant. Test accuracy may change as new SARS-CoV-2 viruses emerge. Additional testing with a lab-based molecular test (e.g., PCR) should be considered in situations when a new virus or variant is suspected.
Device Description
The OHC COVID-19 Antigen Self Test is a lateral flow chromatographic immunoassay intended to detect the nucleocapsid protein antigen from SARS-CoV-2 in non-prescription home use from:
- Self-collected anterior nasal (nares) swab specimens from individuals aged 14 years and older with symptoms of COVID-19 within the first 6 days of symptom onset.
- Adult-collected anterior nasal (nares) swab specimens from individuals aged 2 years and older with symptoms of COVID-19 within the first 6 days of symptom onset.
The OHC COVID-19 Antigen Self Test is based on a lateral flow immunoassay and detects the N-Protein (nucleocapsid protein) of SARS-CoV-2. The cassette contains membranes which are pre-coated with anti-SARS-CoV-2 nucleocapsid protein monoclonal antibodies on test line. Another anti-SARS-CoV-2 nucleocapsid protein monoclonal antibodies are bound to colloidal gold. When the sample is loaded to the sample inlet, SARS-CoV-2 antibodies, that were conjugated with the small colloidal gold articles, and SARS-CoV-2 antigen complexes are formed and travel up the strip. If the sample contains SARS-CoV-2 antigens ("analyte"), the complexes will be captured by coated antibodies on membrane to form an analyte-labeled antibody complex. When these complexes reach the test line of the cassette they are retained by another set of SARS-CoV-2 antibodies. This so-called sandwich complex appears as a visible pink/purple line on the test line (T). The presence of SARS- CoV-2 antigen will be indicated by a visible red test line in T-marked (T) position on side of result window. If the sample does not contain SARS-CoV-2 antigens, no sandwich complexes are formed and thus no colored line appears on the test line (T). Regardless of the presence or absence of SARS-CoV-2 antigens in the sample, a colored line will appear on the control line (C). The control (C) line appears in each result window when sample has flowed through the strip. The control line is used as an internal procedural control. The control line should always appear if the test procedure is performed properly and the reagents are working as intended. If no colored line appears on the control line (C), it implies that the test has not worked as intended.
Ask a Question
K Number
K243262Device Name
QuickFinder COVID-19/Flu Antigen Self Test / QuickFinder COVID-19/Flu Antigen Pro Test
Manufacturer
Osang LLC
Date Cleared
2025-01-13
(90 days)
Product Code
SCA
Regulation Number
866.3987Why did this record match?
Applicant Name (Manufacturer) :
Osang LLC
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The QuickFinder™ COVID-19Flu Antigen Self Test is a lateral flow immunochromatographic assay intended for the qualitative detection and differentiation of influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid protein directly in anterior nasal swab samples from individuals with signs and symptoms of respiratory tract infection. Symptoms of respiratory infections due to SARS-CoV-2 and influenza can be similar. This test is for nonprescription home use by individuals aged 14 years or older testing themselves, or adults testing individuals aged 2 years or older.
All negative results are presumptive and should be confirmed with an FDA-cleared molecular assay when determined to be appropriate by a healthcare provider. Negative results do not rule out influenza, SARS-CoV-2 or other pathogens. Individuals who test negative and experience continued or worsening respiratory symptoms, such as fever, cough and/or shortness of breath, should seek follow-up care from their healthcare provider.
Positive results do not rule out co-infection with other respiratory pathogens and therefore do not subsition for a visit to a healthcare provider or appropriate follow-up.
QuickFinder™ COVID-19/Flu Antigen Pro Test
The QuickFinder™ COVID-19/Flu Antigen Pro Test is a lateral flow immunochromatographic assay intended for the qualitative detection and differentiation of influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid protein directly in anterior nasal swab samples from individuals with signs and symptoms of respiratory tract infection. Symptoms of respiratory infections due to SARS-CoV-2 and influenza can be similar. This test is for use by individuals aged 14 years or older testing themselves, or adults testing individuals aged 2 years or older.
All negative results are presumptive and should be confirmed with an FDA-cleared molecular assay when determined to be appropriate by a healthcare provider. Negative results do not rule out influenza, SARS-CoV-2 or other pathogens. Individuals who test negative and experience continued or worsening respiratory symptoms, such as fever, cough and/or shortness of breath, should seek follow-up care from their healthcare provider.
Positive results do not rule out co-infection with other respiratory pathogens and therefore do not subsition for a visit to a healthcare provider or appropriate follow-up.
Device Description
The QuickFinder™ COVID-19/Flu Antigen Self Test / QuickFinder™ COVID-19/Flu Antigen Pro Test is a rapid lateral flow test for the qualitative detection of the SARS-CoV-2, Influenza A and Influenza B using anterior nares nasal swab samples from those who are suspected of COVID-19, Influenza A, and Influenza B. The QuickFinder™ COVID-19/Flu Antigen Self Test / QuickFinder™ COVID-19/Flu Antigen Pro Test is validated for testing direct samples without transport media.
The lateral flow test is for:
- . Self-collected anterior nasal (nares) swab specimens from individuals aged 14 years and older with symptoms of COVID-19 within the first 4 days of symptom onset.
- Adult-collected anterior nasal (nares) swab specimens from individuals aged 2 years ● and older with symptoms of COVID-19 within the first 4 days of symptom onset.
The QuickFinder™ COVID-19/Flu Antigen Self Test / QuickFinder™ COVID-19/Flu Antigen Pro Test is a lateral flow test. The cassette contains membranes which are pre-coated with anti-SARS-CoV-2 nucleocapsid protein monoclonal antibodies, anti-influenza A nucleoprotein monoclonal antibodies and anti-influenza B nucleoprotein monoclonal antibodies on the test lines. Another anti-SARS-CoV-2 nucleocapsid protein monoclonal antibodies, anti-influenza A nucleoprotein monoclonal antibodies and anti-influenza B nucleoprotein monoclonal antibodies are each bound to the beads. When the sample is put into the sample well, the antibodies bound to the beads and the antigen in the sample bind to form complexes and migrate to the membrane. The complexes will be captured by coated antibodies on the membrane, and then the line will form a visible line. The presence of SARS-CoV-2, influenza A and influenza B antigens are indicated by lines visible in the Smarked position, A-marked position, and B-marked position in the results window, respectively. If no colored line appears on the control line (C), it implies that the test has not worked as intended.
Ask a Question
Page 1 of 1